Arcellx (ACLX) Q2 Revenue Drops 72%
Arcellx (NASDAQ:ACLX), a biotechnology company developing cell therapies for blood cancers and autoimmune diseases, reported its second quarter 2025 results on August 7, 2025. The most notable update centered on a sharp revenue miss and a wider net loss, even as key clinical milestones advanced for its lead CAR-T cell therapy, anito-cel. Collaboration revenue (GAAP) was $7.6 million, falling short of analyst expectations of $13.52 million (GAAP). General and administrative expenses related to commercial readiness grew, while research and development expenses declined, driving the net loss (GAAP) to $52.8 million. The period was defined by a major data update from its pivotal clinical trial but also by financial pressures as the company transitions toward commercialization.
Source: Analyst estimates for the quarter provided by FactSet.
Arcellx develops therapies using its proprietary D-Domain technology, a synthetic binding scaffold designed to improve upon standard chimeric antigen receptor T cell (CAR-T) approaches. The company focuses on novel cell therapies for patients with relapsed or refractory multiple myeloma and is advancing other programs for autoimmune and solid tumor conditions.
Source Fool.com
